CSIMarket
 
Regenerx Biopharmaceuticals inc   (RGRX)
Other Ticker:  
 

Regenerx Biopharmaceuticals inc

Business Description


Regenerx Biopharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative tissue repair and therapeutic products. The company is primarily engaged in the research and development of novel biologic products for the treatment of various diseases and conditions including cardiovascular diseases, ophthalmic disorders, and orthopedic injuries.

Regenerx was founded in 1983 and is headquartered in Bethesda, Maryland. The company*s main product candidate is Thymosin beta 4 (TB4), a naturally occurring peptide that plays a crucial role in tissue repair and regeneration. TB4 has shown promising results in preclinical and clinical trials for the treatment of various diseases and injuries.

Regenerx has conducted extensive research and development on TB4, including investigating its potential in accelerating wound healing, reducing inflammation, and improving tissue regeneration. The company has developed proprietary formulations of TB4 for different therapeutic applications, such as dermal wound healing, ocular surface repair, and cardiac tissue regeneration.

One of the key areas of focus for Regenerx is ophthalmic disorders, specifically dry eye disease. Dry eye disease is a common condition characterized by insufficient tear production or poor tear quality, leading to discomfort and visual disturbances. Regenerx has conducted clinical trials to evaluate the efficacy and safety of TB4 in treating dry eye disease and has reported positive results, demonstrating its potential as a therapeutic option.

In addition to dry eye disease, Regenerx is also exploring the potential of TB4 in treating other ocular disorders, including diabetic retinopathy, corneal ulcers, and optic nerve injury. The company has ongoing preclinical and clinical trials to evaluate the efficacy and safety of TB4 in these indications.

Regenerx*s research and development efforts also extend to cardiovascular diseases, particularly in the field of cardiac tissue repair and regeneration. The company has conducted preclinical studies showing the potential of TB4 in improving cardiac function and promoting tissue repair after a heart attack. Regenerx is currently working towards developing a therapeutic product for cardiac tissue regeneration using TB4.

The company has an experienced scientific team and has established collaborations with academic institutions and medical centers to further its research and development goals. These collaborations provide access to expertise, resources, and patient populations necessary for conducting clinical trials and advancing the development of its product candidates.

Overall, Regenerx Biopharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative biologic products for tissue repair and regeneration. Through its primary product candidate, Thymosin beta 4, the company aims to address unmet medical needs in various disease areas, including cardiovascular diseases and ophthalmic disorders. With positive preclinical and clinical trial results, Regenerx continues to make advancements in its research and development efforts to bring novel therapies to patients in need.



View Company Supplier View Company Competition View Company Customers


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com